It’s an absolute pharmaceutical revolution as eMed CEO Linda Yaccarino and Chief Wellness Officer, seven-time Super Bowl champion, and FOX Sports lead NFL analyst Tom Brady join the Claman Countdown to talk about democratizing affordable, FDA-approved GLP-1 access through employers. Linda highlights how eMed leverages AI and clinical support to double industry standards for patient adherence, and Tom shares how he is translating his legendary NFL discipline straight into the corporate workforce. Later, he discusses his third season in the FOX Sports booth and his expectations for the Las Vegas Raiders&#x27; rookie quarterback Fernando Mendoza. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The GLP-1 Revolution: Tom Brady & Linda Yaccarino’s Playbook for Health

Everyone Talks To Liz Claman

4, 5, 8, 9, 8, 9, 0, 1, 0, 1, 4, ah. Schluss mit dem ewigen Abtippen von Kartennummern. Dank Visa Click to Pay. Ohne 16-stellige Kartennummern einzugeben, Passwörter nachzuschlagen oder extra Apps herunterladen zu müssen. So kommst du beim Online-Shoppen direkt ans Ziel. Mach online bezahlen einfach, schnell, sicher. Mit Visa Click to Pay. Einfach beim nächsten Checkout auswählen.

Novo Nordisk breaking the news today that it has gotten the seal of approval from the European Health Commission, which would make Novo's Wagovi pill form the first approved oral GLP-1 for weight management in the European Union. And Novo Nordisk's GLP-1 Wagovi pill has pulled ahead of rival Eli Lilly's Fondeo pill by a mile, with Lilly now capturing 11% of the market for new prescription GLP-1 pills and Novo dominating the rest.

Novo Nordisk shares up about 3%. You've got Lilly flat to slightly higher. Doctors point to stronger weight loss results and faster insurance coverage as key reasons. And that brings us to eMed. The digital health company is looking to change how patients get care, and in particular how companies get access to expensive GLP-1 medications for their employees. Joining me now on a Fox Business exclusive, Linda Yaccarino, eMed CEO and former CEO of X,

along with Tom Brady, eMed's chief wellness officer, who also happens to be a seven-time Super Bowl champ, NFL legend and Fox Sports NFL analyst. Hi, Tom. Hi, Linda. Great to have you both. Thanks for having us. Good afternoon. It's great to be here. Linda, let me start with you. There is no longer a shortage in GLP-1s. So let's talk about what eMed can actually do and the premise of your company. What can you offer employers when it comes to GLP-1s and then the follow-up healthcare?

The GLP-1 Revolution: Tom Brady & Linda Yaccarino’s Playbook for Health

Read the full transcript

The candid version is on a podcast,
not the earnings call.

The GLP-1 Revolution: Tom Brady & Linda Yaccarino’s Playbook for Health

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.